These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28515962)

  • 1. Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
    McNiel EA; Tsichlis PN
    Signal Transduct Target Ther; 2017; 2():16045-. PubMed ID: 28515962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway.
    Sanches JGP; Song B; Zhang Q; Cui X; Yabasin IB; Ntim M; Li X; He J; Zhang Y; Mao J; Lu Y; Li L
    Front Oncol; 2021; 11():637298. PubMed ID: 33791221
    [No Abstract]   [Full Text] [Related]  

  • 4. Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4.
    Chavdoula E; Anastas V; Ferlita A; Aldana J; Carota G; Spampinato M; Soysal B; Cosentini I; Parashar S; Sircar A; Nigita G; Sehgal L; Freitas MA; Tsichlis PN
    bioRxiv; 2023 Jul; ():. PubMed ID: 37461630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells.
    Kornmann M; Lopez ME; Beger HG; Korc M
    Int J Pancreatol; 2001; 29(2):85-92. PubMed ID: 11876253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
    Kuang Y; Lu F; Guo J; Xu H; Wang Q; Xu C; Zeng L; Yi S
    Onco Targets Ther; 2017; 10():3131-3144. PubMed ID: 28706445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addiction of mesenchymal phenotypes on the FGF/FGFR axis in oral squamous cell carcinoma cells.
    Osada AH; Endo K; Kimura Y; Sakamoto K; Nakamura R; Sakamoto K; Ueki K; Yoshizawa K; Miyazawa K; Saitoh M
    PLoS One; 2019; 14(11):e0217451. PubMed ID: 31682640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative splicing of fibroblast growth factor receptors in human prostate cancer.
    Kwabi-Addo B; Ropiquet F; Giri D; Ittmann M
    Prostate; 2001 Feb; 46(2):163-72. PubMed ID: 11170144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
    Segovia C; Martínez-Fernández M; Dueñas M; Rubio C; López-Calderón FF; Costa C; Saiz-Ladera C; Fernández-Grajera M; Duarte J; Muñoz HG; de la Rosa F; Villacampa F; Castellano D; Paramio JM
    Oncotarget; 2017 Feb; 8(6):10531-10542. PubMed ID: 28060766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
    Wang Y; Zang J; Zhang D; Sun Z; Qiu B; Wang X
    Onco Targets Ther; 2018; 11():201-209. PubMed ID: 29386904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
    Peta E; Sinigaglia A; Masi G; Di Camillo B; Grassi A; Trevisan M; Messa L; Loregian A; Manfrin E; Brunelli M; Martignoni G; Palù G; Barzon L
    Oncogene; 2018 Mar; 37(12):1654-1668. PubMed ID: 29335520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
    Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Alkahtani S; Alarifi S; Tsichlis PN; Kampranis SC; Stournaras C
    Cell Physiol Biochem; 2018; 47(1):368-377. PubMed ID: 29772566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness of developing dental tissues to fibroblast growth factors: expression of splicing alternatives of FGFR1, -2, -3, and of FGFR4; and stimulation of cell proliferation by FGF-2, -4, -8, and -9.
    Kettunen P; Karavanova I; Thesleff I
    Dev Genet; 1998; 22(4):374-85. PubMed ID: 9664689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of several waves of gene expression during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells.
    Billottet C; Tuefferd M; Gentien D; Rapinat A; Thiery JP; Broët P; Jouanneau J
    J Cell Biochem; 2008 Jun; 104(3):826-39. PubMed ID: 18189245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.